Buchumschlag

Editorial: Tenofovir Alafenamide Versus Entecavir for Hepatitis B Surface Antigen Decline–A Step Toward Functional Cure or a Marginal Margin?

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Yao‐Chun Hsu, Ming‐Lung Yu
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2026
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Superior Efficacy of Tenofovir Alafenamide Compared With Entecavir in Reducing Hepatitis B Surface Antigen: A Multicentre Propensity Score‐Matched Study Using Linear Mixed‐Effects Models
von: Takashi Kumada, et al.
Veröffentlicht: (2026)

Tenofovir Alafenamide Therapy Throughout Pregnancy in Mothers With Hepatitis B
von: Xingfei Pan, et al.
Veröffentlicht: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors—Authors' Reply
von: Ying‐Nan Tsai, et al.
Veröffentlicht: (2025)

Letter: Tenofovir Alafenamide—The “Star of Potential” for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials
von: YaoYao Dai, et al.
Veröffentlicht: (2025)

Letter: Reassessing Tenofovir Alafenamide Use Throughout Pregnancy—A New Horizon in Hepatitis B Therapy. Authors' Reply
von: Xingfei Pan, et al.
Veröffentlicht: (2025)

Efficacy and Safety of Tenofovir Alafenamide (TAF) and Tenofovir Disoproxil Fumarate (TDF) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment
von: Grace Lai‐Hung Wong, et al.
Veröffentlicht: (2025)

Letter on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment”
von: Yan Liu, et al.
Veröffentlicht: (2025)

Letters on “Efficacy and Safety of Tenofovir Alafenamide ( TAF ) and Tenofovir Disoproxil Fumarate ( TDF ) Followed by TAF in Chronic Hepatitis B Patients of East Asian Ethnicity Following 5 Years of Treatment.” Authors' Reply
von: Grace Lai‐Hung Wong, et al.
Veröffentlicht: (2025)

Editorial: Flipping the Script—Higher Risk of Hepatocellular Carcinoma With Tenofovir Compared to Entecavir in a French Population‐Based Cohort
von: Ariel Lee, et al.
Veröffentlicht: (2025)

Letter: “Tenofovir Alafenamide—The ‘Star of Potential’ for Long‐Term Chronic Hepatitis B Treatment. A Deep‐Dive Analysis of Phase 3 Clinical Trials.” Authors' Reply
von: Maria Buti
Veröffentlicht: (2025)

Editorial: Beyond Viral Eradication—Scrutinising Outcomes After Hepatitis C Cure
von: Wei‐Fan Hsu, et al.
Veröffentlicht: (2025)

Editorial: The Relevance of Hepatic Flares and Quantitative Hepatitis B Surface Antigen After Stopping HBV Polymerase Inhibitors
von: Stefan Mauss
Veröffentlicht: (2025)

Editorial: HBeAg ‐Positive Chronic Hepatitis B With Low HBsAg Levels—Exploring Clinical Significance of preS2 Deletion Mutations
von: Ying‐Nan Tsai, et al.
Veröffentlicht: (2025)

Genetic Determinants of Spontaneous Hepatitis B Surface Antigen Seroclearance and Its Associated Viral Markers
von: Jun Tao, et al.
Veröffentlicht: (2026)

Editorial: Beyond Viral Eradication—Cardiometabolic Risk and Cardiovascular Outcomes After SVR in Chronic Hepatitis C. Authors' Reply
von: Pei‐Chien Tsai, et al.
Veröffentlicht: (2026)

Editorial: A Step Back to Leap Forward—Strategic Nucleos(t)ide Analogue Discontinuation Towards HBV Functional Cure
von: Xuwen Xu, et al.
Veröffentlicht: (2025)

Editorial: Ultralow HBsAg Levels and the Prediction of Cure in Chronic Hepatitis B—Authors' Reply
von: Jian Wang, et al.
Veröffentlicht: (2025)

Factors Associated With Underutilization of Antiviral Therapy in Preventing Hepatitis B Virus‐Related Hepatocellular Carcinoma
von: Jia‐Ling Wu, et al.
Veröffentlicht: (2025)

Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Authors' Reply
von: Yu‐Sheng Lin, et al.
Veröffentlicht: (2026)

CD300A+CD8+ T Cells as Predictive Biomarkers for Achieving Functional Cure in Chronic Hepatitis B Patients Undergoing Pegylated Interferon‐Alpha Therapy
von: Peng Zhang, et al.
Veröffentlicht: (2025)

Surviving Hepatitis C—Understanding Death and Survival Beyond Cure
von: Paul J. Clark, et al.
Veröffentlicht: (2025)

Editorial: Using HBcrAg and HBsAg Kinetics to Optimise Monitoring After Nucleo(s)tide Analogue Withdrawal. Authors' Reply
von: Yasuhito Tanaka, et al.
Veröffentlicht: (2026)

Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
von: Yu‐Ping Chang, et al.
Veröffentlicht: (2025)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection—Authors' Reply
von: Yu‐Ping Chang, et al.
Veröffentlicht: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
von: Jee‐Fu Huang, et al.
Veröffentlicht: (2026)

Editorial: Risk of Incident Type 2 Diabetes and Prediabetes in Patients With Direct Acting Antiviral‐Induced Cure of Hepatitis C Virus Infection
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2025)

Editorial: Advancing HCC Surveillance in Hepatitis B With Biomarker‐Based Strategy
von: Yu Jun Wong
Veröffentlicht: (2025)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate—Authors' Reply
von: Ying‐Nan Tsai, et al.
Veröffentlicht: (2025)

Air Pollution Associated With Mortality Among Chronic Hepatitis B Patients Treated With Nucleotide/Nucleoside Analogues
von: Tyng‐Yuan Jang, et al.
Veröffentlicht: (2025)

Letter: Reconsidering Tenofovir Disoproxil Fumarate Use in Light of Emerging Safety Evidence
von: Priyadarshini Zula, et al.
Veröffentlicht: (2026)

Letter: Double‐Dose Hepatitis B Vaccination in IBD —A Step Forward in Protecting Immunosuppressed Patients
von: Luisa Bertin, et al.
Veröffentlicht: (2026)

Letter: Advancing Serologic Classification in Indeterminate Chronic Hepatitis B Through Dynamic and Integrated Frameworks
von: Chun‐Chieh Chen, et al.
Veröffentlicht: (2025)

Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease
von: Anupam Kumar Singh, et al.
Veröffentlicht: (2025)

Distribution, Characteristics, and Natural History of Diverse Types of Indeterminate Chronic Hepatitis B: A REAL‐B Study
von: Rui Huang, et al.
Veröffentlicht: (2025)

Letter: Trajectories of Hepatic Function Markers Enable Early Prediction of Hepatic Recompensation
von: Benedikt Silvester Hofer, et al.
Veröffentlicht: (2026)

Hepatic Events During Immune Checkpoint Inhibitor Treatment Between Liver and Non‐Liver Malignancies in Hepatitis B Endemic Areas
von: Yi‐Ping Hung, et al.
Veröffentlicht: (2024)

Editorial: Breath Profiling in MASLD—A Step Towards Better Risk Stratification
von: Takefumi Kimura
Veröffentlicht: (2025)

Editorial: Chronic Hepatitis B at the Intersection of Immigration, Acculturation and Social Determinants of Health
von: Thomas Hoang, et al.
Veröffentlicht: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
von: Karen Cheuk‐Ying Ho, et al.
Veröffentlicht: (2025)

Advanced Fibrosis and Cardiometabolic Risk Burden Increase Major Cardiovascular Events in Chronic Hepatitis C Patients With Steatotic Liver Disease After Viral Eradication
von: Pei‐Chien Tsai, et al.
Veröffentlicht: (2025)